ACADACADIA Pharmaceuticals Inc.

$4B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$115M+4.6% YoY

Gross Profit

$110M95.5% margin

Operating Income

-$44M-37.9% margin

Net Income

-$44M-38.1% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

+8.1%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$724M

Total Liabilities

$160M

Stockholders' Equity

$565M

Cash & Equivalents

$267M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$115M	$110M	+4.6%
Gross Profit	$110M	$105M	+5.1%
Operating Income	-$44M	-$44M	+0.7%
Net Income	-$44M	-$42M	-4.1%

ACAD Q2 2021 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena